IL274202A - Antibodies against Glyco-Moc1 and uses thereof - Google Patents

Antibodies against Glyco-Moc1 and uses thereof

Info

Publication number
IL274202A
IL274202A IL274202A IL27420220A IL274202A IL 274202 A IL274202 A IL 274202A IL 274202 A IL274202 A IL 274202A IL 27420220 A IL27420220 A IL 27420220A IL 274202 A IL274202 A IL 274202A
Authority
IL
Israel
Prior art keywords
glyco
muc1 antibodies
muc1
antibodies
Prior art date
Application number
IL274202A
Other languages
English (en)
Hebrew (he)
Original Assignee
Go Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Go Therapeutics Inc filed Critical Go Therapeutics Inc
Publication of IL274202A publication Critical patent/IL274202A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL274202A 2017-10-24 2020-04-23 Antibodies against Glyco-Moc1 and uses thereof IL274202A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/058036 WO2019083506A1 (en) 2017-10-24 2017-10-24 ANTI-GLYCO-MUC1 ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
IL274202A true IL274202A (en) 2020-06-30

Family

ID=66247577

Family Applications (1)

Application Number Title Priority Date Filing Date
IL274202A IL274202A (en) 2017-10-24 2020-04-23 Antibodies against Glyco-Moc1 and uses thereof

Country Status (10)

Country Link
EP (1) EP3700936A4 (enExample)
JP (2) JP7358367B2 (enExample)
KR (2) KR102608763B1 (enExample)
CN (1) CN111479828B (enExample)
AU (1) AU2017436815B2 (enExample)
BR (1) BR112020008001A2 (enExample)
CA (1) CA3078812A1 (enExample)
IL (1) IL274202A (enExample)
MX (1) MX2020004220A (enExample)
WO (1) WO2019083506A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102608763B1 (ko) * 2017-10-24 2023-11-30 고 테라퓨틱스, 인크. 항-글리코-muc1 항체 및 이의 용도
AU2021316098A1 (en) * 2020-07-31 2023-03-16 R.P. Scherer Technologies, Llc Antibody specific for Mucin-1 and methods of use thereof
US20250129180A1 (en) * 2021-08-27 2025-04-24 Peptron, Inc. Novel anti-muc1 antibody and use thereof
AU2022420709A1 (en) * 2021-12-21 2024-08-01 Merus N.V. Binding domains against cancer-associated muc1
CN114796498A (zh) * 2022-01-27 2022-07-29 中国农业大学 抑制muc1糖基化修饰的物质在提高乳腺癌细胞对抗乳腺癌药物的敏感度中的应用
WO2024213106A1 (zh) * 2023-04-13 2024-10-17 江苏恒瑞医药股份有限公司 特异性结合egfr和muc1的抗原结合分子、其药物偶联物及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020146750A1 (en) * 2000-03-30 2002-10-10 Hoogenboom Hendricus R.J.M. Mucin-1 specific binding members and methods of use thereof
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
JP2010505775A (ja) * 2006-10-04 2010-02-25 クーベンハヴンス・ユニヴェルシテット Ｍｕｃ１に対する癌特異的な免疫反応の産生及び癌特異的ｍｕｃ１抗体
EP2014302A1 (en) * 2007-07-12 2009-01-14 Institut Curie An antibody specific for the Tn antigen for the treatment of cancer
AU2008332296A1 (en) * 2007-12-05 2009-06-11 Kyowa Hakko Kirin Co., Ltd. Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
CN102264765B (zh) * 2008-10-28 2016-01-20 盐野义制药株式会社 抗muc1抗体
EP2281844A1 (en) * 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015120180A1 (en) * 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants
US10239950B2 (en) * 2014-04-28 2019-03-26 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Anti-MUC1 antibody or antigen-binding fragment thereof and uses thereof
KR102608763B1 (ko) * 2017-10-24 2023-11-30 고 테라퓨틱스, 인크. 항-글리코-muc1 항체 및 이의 용도

Also Published As

Publication number Publication date
EP3700936A1 (en) 2020-09-02
JP2021510307A (ja) 2021-04-22
BR112020008001A2 (pt) 2020-10-20
MX2020004220A (es) 2020-10-05
JP2024001073A (ja) 2024-01-09
KR20230165874A (ko) 2023-12-05
EP3700936A4 (en) 2021-05-26
JP7358367B2 (ja) 2023-10-10
KR20200067885A (ko) 2020-06-12
KR102608763B1 (ko) 2023-11-30
CN111479828A (zh) 2020-07-31
CN111479828B (zh) 2024-07-05
AU2017436815B2 (en) 2025-05-29
WO2019083506A1 (en) 2019-05-02
CA3078812A1 (en) 2019-05-02
AU2017436815A1 (en) 2020-04-23
KR102832078B1 (ko) 2025-07-08

Similar Documents

Publication Publication Date Title
IL324062A (en) Anti-CD73 antibodies and their uses
ZA202102905B (en) Anti-galectin-9 antibodies and uses thereof
ZA202101318B (en) Anti-phf-tau antibodies and uses thereof
IL271477A (en) Anti-cd166 antibodies and their uses
ZA202105676B (en) Anti-trem2 antibodies and related methods
IL268734A (en) Anti-LAG-3 antibodies and uses thereof
IL272218A (en) ANTI-SIRP-ALPHA ANTIBODIES AND RELATED METHODS
IL266738A (en) Novel antibodies and their uses
IL269134A (en) Antibodies against PAR2 and their use
SG11201808632YA (en) Anti-pacap antibodies and uses thereof
ZA201901935B (en) Anti-il-33 antibodies and uses thereof
IL254517B (en) Antibodies against muc16 and their uses
IL254954A0 (en) Anti-pacap antibodies and their uses
IL273157A (en) Antibodies specific to AXL and their uses
IL272476A (en) Anti-Apelin antibodies and their uses
IL266082A (en) Anti-chikv antibodies and their use
IL266049A (en) Antibodies against o1 and their uses
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof
IL274202A (en) Antibodies against Glyco-Moc1 and uses thereof
IL264417A (en) Anti-o2 antibodies and their uses
GB201712032D0 (en) Antibodies and uses thereof
GB201820334D0 (en) Antibodies and their uses